IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Paul Habermann

Application No.: **10/076,631**

Filed: **February 19, 2002**

Title: **NUCLEIC ACIDS ENCODING A HIRUDIN AND PRO-INSULIN AS SUPERSCRETABLE PEPTIDES AND FOR PARALLEL IMPROVEMENT OF THE EXPORTED FORMS OF ONE OR MORE POLYPEPTIDES OF INTEREST**

Examiner: KOSSON, Roseanne

Art Unit: 1652

Confirmation No.: **2601**

CERTIFICATE OF EFS-WEB TRANSMISSION

I hereby certify that the correspondence below is being transmitted via the USPTO's electronic filing system in accordance with 1.6(a)(4), on the date indicated below.

Date of Deposit July 9. 2010

Printed Name of Person Signing Certificate Delia Coughlin

Signature /Delia Coughlin/

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 35 U.S.C. 254/255 and 37 C.F.R. 1.322/323

Commissioner for Patents
Attn: Certificate of Correction Branch
P. O. Box 1450
Alexandria, VA 22313-1450

The following is a request for a certificate of correction in Serial Number 10/076,631, now patent Number 7,638,618.

A certificate of correction under 35 U.S.C. 254 is respectfully requested in the above-identified patent.

☐ All errors were the fault of the USPTO, no fee required. In the event that a further fee is required, please charge the amount to Deposit Account No. **18-1982.**

☐ All errors were the fault of the applicant and, accordingly, please charge $**100.00** to our Deposit Account No. **18-1982**. In the event that a further fee is required, please charge the amount to the same Deposit Account.

☒ The errors were the fault of both the applicant and the USPTO and, accordingly, please charge $**100.00** to our Deposit Account No. **18-1982**. In the event that a further fee is required, please charge the amount to the same Deposit Account.

The exact location where the error appears in the patent and patent application is noted below.

The requested correction is attached on Form PTO 1050.

EXACT LOCATION WHERE ERRORS APPEAR

1. In column 7, line 55 (Page 3, Amendments to the Specification, (05/19/2006), line 31): "(Refludan®)" should read as - - (REFLUDAN®) - -.

2. In column 8, line 2 (Page 17, Specification, (02/19/2002), line 16): "hirF1" should read as - - hIRF1 - -.

3. In column 9, line 67 (Page 4, Amendments to the Specification, (05/19/2006), line 4): "REFLUDAN®." should read as - - REFLUDAN® - -.

4. In column 10, line 10 (Page 4, Amendments to the Specification, (05/19/2006), line 7): "INVITROGEN®." should read as - - INVITROGEN® - -.

5. In column 10, line 30 (Page 23, Specification, (02/19/2002), line 9): "primer Pichia" should read as - - Primer pichia - -.

6. In column 10, line 46 (Page 23, Specification, (02/19/2002), line 20): "zeocine" should read as - - zeocin - -.

7. In Claim 6, (see Claim 10 as presented by Amendment filed Jul. 16, 2009): column 16, line 50: "factis," should read as - - lactis, - -.

Respectfully submitted,

/George S Jones/
George S. Jones, Reg. No. 38,508
Attorney for Applicant

Sanofi-aventis U.S. Inc.
U.S. Patent Operations
Mail Code: BWD-303A
1041 Route 202-206
Bridgewater, New Jersey 08807
Telephone (908) 231-**3776**
Telefax (908) 231-2626
Sanofi-aventis U.S. Docket No. DEAV2001/0007
Date: July 8, 2010

PTO/SB/44 (09-07)
Approved for use through 08/31/2010. OMB 0651-0033
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

(Also Form PTO-1050)

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,638,618

APPLICATION NO.: 10/076,631

ISSUE DATE : December 29, 2009

INVENTOR(S) : Paul Habermann

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

In column 7, line 55, delete “(Refludan®)” and insert - - (REFLUDAN®) - -, therefor.

In column 8, line 2, delete “hirF1” and insert - - hIRF1 - -, therefor.

In column 9, line 67, delete “REFLUDAN®.” and insert - - REFLUDAN® - -, therefor.

In column 10, line 10, delete “INVITROGEN®.” and insert - - INVITROGEN® - -, therefor.

In column 10, line 30, delete “primer Pichia” and insert - - Primer pichia - -, therefor.

In column 10, line 46, delete “zeocine” and insert - - zeocin - -, therefor.

In column 16, line 50, in Claim 6, delete “factis,” and insert - - lactis, - -, therefor.

MAILING ADDRESS OF SENDER (Please do not use customer number below)

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.